New Oral Anticoagulants Use in Renal Disease and Af (noacure-Af) - Where Do We Stand?: an Expert Consensus View Using the Delphi Method

Arici M.Ecder T.Erdinler I.Ok E.Özlük Ö.A.Türk U.Ö.Alio?lu E.2023-06-162023-06-1620211016-51691308-4488https://doi.org/10.5543/TKDA.2021.40652https://search.trdizin.gov.tr/yayin/detay/486144https://hdl.handle.net/20.500.14365/3828[No abstract available]trinfo:eu-repo/semantics/openAccessanticoagulant agentantifibrinolytic agentantithrombinwarfarinatrial fibrillationconsensusDelphi studyhumankidney diseaseReviewscientific literatureadverse eventatrial fibrillationcerebrovascular accidentchronic kidney failurecomplicationdiabetic complicationheart failurehemodialysishypertensionoral drug administrationrisk factorvascular diseaseAdministration, OralAntifibrinolytic AgentsAntithrombinsAtrial FibrillationConsensusDelphi TechniqueDiabetes ComplicationsHeart FailureHumansHypertensionKidney Failure, ChronicRenal DialysisRenal Insufficiency, ChronicRisk FactorsStrokeVascular DiseasesWarfarinNew Oral Anticoagulants Use in Renal Disease and Af (noacure-Af) - Where Do We Stand?: an Expert Consensus View Using the Delphi MethodBöbrek Hastali?i Olan Af Olgularinda Non-vitamin K Antagonisti Oral Antikoagülanlarin Kullanimi (noacure-af) - Neredeyiz?: Delphi Yöntemi Kullanan Bir Uzman Uzlaşi RaporuReview10.5543/TKDA.2021.406522-s2.0-85110345161